“…statins in less than 60%, see Tables 2 and 3 [10]), and the unadjusted cox regression analysis. Nevertheless, with the high unlikeliness for a "sunrise" of a TASC III classification combining clinical and angiographic outcome predictors, the current report is one of the few investigations [10,11] to try to overcome the limitations of Fontaine, Rutherford or TASC I and TASC II.…”